DEF: Avalon GloboCare Sets 2025 Annual Meeting, Announces CEO Transition

Avalon GloboCare Corp. announced its 2025 Annual Meeting of Stockholders to be held virtually on December 30, 2025, alongside the resignation of CEO Dr. David Jin and the appointment of Meng Li as interim CEO.

Summary

• The 2025 Annual Meeting of Stockholders will be held virtually on Tuesday, December 30, 2025, at 9:00 a.m. Eastern Time.
• Stockholders will vote on the election of six director nominees and the ratification of M&K CPAS, PLLC as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
• Dr. David Jin resigned as Chief Executive Officer and director, effective November 30, 2025, due to a personal health issue.
• Ms. Meng Li, current Chief Operating Officer, has been appointed interim Chief Executive Officer, effective November 30, 2025.
• The company reported a net loss of $7,903,394 for 2024, an improvement from a $16,707,010 net loss in 2023.
• Executive salaries for Dr. David Jin and Ms. Meng Li were reduced in 2024 as part of company cost reduction measures.
• The Board has commenced a search for a director to fill the vacancy created by Dr. Jin's resignation.

Sentiment

Score: 3

Explanation: The filing indicates a significant decline in shareholder value (TSR from $100 to $4) and ongoing net losses, despite an improvement from the prior year. The CEO's resignation and interim appointment add uncertainty. While cost reduction measures and some related-party transactions provide capital, the overall financial performance and shareholder returns are poor.

Positives

• Net loss significantly decreased from $16,707,010 in 2023 to $7,903,394 in 2024, indicating improved financial performance.
• Executive salaries for the CEO and COO were reduced in 2024 as part of company cost reduction measures, demonstrating a focus on expense management.
• The company successfully redeemed a 40% equity interest in Lab Services MSO for $1,745,000 cash and the surrender of $11,000,000 in Series B Preferred Stock, resulting in a $2,348,695 increase to additional paid-in capital.
• The company's Line of Credit from Chairman Wenzhao Daniel Lu, which provided $20 million, was fully repaid or reclassified by December 31, 2024, reducing direct debt to a related party.

Negatives

• The company reported a net loss of $7,903,394 for the fiscal year ended December 31, 2024.
• Total Shareholder Return (TSR) showed a significant decline, with a $100 investment on December 31, 2022, valued at only $4 by December 31, 2024.
• The CEO, Dr. David Jin, resigned due to a personal health issue, which could introduce leadership uncertainty.
• The company is still operating at a loss, despite the reduction from the previous year.

Risks

• The filing refers to 'Risk Factors' in the company's 2024 Annual Report and other SEC filings, but does not detail specific risks within this proxy statement.
• Leadership transition with the CEO's resignation and interim appointment could introduce operational or strategic risks.
• Continued net losses, despite improvement, indicate ongoing financial challenges.
• The low Total Shareholder Return suggests significant erosion of shareholder value.

Future Outlook

The company expects the acquisition of 30% of Avalon RT 9 by Chairman Wenzhao Daniel Lu to close in the fourth quarter of 2025. Monthly payments from the Lab Services MSO redemption are scheduled to continue until December 2026.

Management Comments

• Our Board believes that the election of the director nominees identified herein (Proposal No. 1), and the appointment of M&K as our independent registered public accounting firm for the year ending December 31, 2025 (Proposal No. 2) are advisable and in the best interests of the Company and its stockholders.
• Our Board has commenced a search for a director to fill the vacancy that will be created on November 30, 2025 by Dr. Jin's resignation.
• Our Board believes its administration of its risk oversight function has not affected its leadership structure.
• Our management has no reason to believe that any nominee will be unable to serve.

Industry Context

This filing primarily focuses on corporate governance matters, executive compensation, and related party transactions, rather than specific operational or scientific advancements. The company operates in the biotechnology and healthcare sectors, which are typically characterized by high R&D costs and potential for significant losses in early stages. The reported net loss, while improved, is common for companies in this industry, especially those focused on development. The low Total Shareholder Return suggests that the market has not seen significant value creation, which can be a challenge for smaller biotech firms without clear commercialization pathways or strong pipeline news.

Comparison to Industry Standards

• The significant decline in Total Shareholder Return (TSR) from $100 to $4 over two years is substantially worse than industry benchmarks for established biotechnology companies, which often aim for positive returns or at least less severe declines. For example, a company like Amgen (AMGN) or Gilead Sciences (GILD) would typically show more stable or growing TSR over a similar period, reflecting mature product portfolios.
• The continued net losses, even with improvement, contrast with profitable, larger-cap biotech firms. However, it is not uncommon for smaller, development-stage biotech companies to incur losses for extended periods, similar to early-stage companies like smaller biopharma startups or emerging medical device firms that are heavily investing in R&D without significant revenue streams.
• The executive compensation structure, primarily fixed cash compensation, differs from many larger biotech companies that heavily rely on performance-based equity awards tied to specific milestones (e.g., clinical trial success, regulatory approvals, revenue targets) to align executive incentives with shareholder value creation.
• The extensive related-party transactions, particularly with the Chairman of the Board, might be viewed with more scrutiny compared to industry best practices for corporate governance, which typically emphasize arm's-length transactions to avoid potential conflicts of interest.

Management Changes

Corporate Governance

Legal Proceedings

• No pending litigation or proceeding involving any directors, officers, employees, or agents in which indemnification will be required or permitted.
• No awareness of any threatened litigation or proceeding that may result in a claim for such indemnification.

Related Party Transactions

• Rental revenue of $50,400 for both 2024 and 2023 from D.P. Capital Investments LLC, controlled by Chairman Wenzhao Daniel Lu, for commercial real property space.
• Consulting expenses of $63,644 in 2024 and $86,528 in 2023 paid to Director Wilbert Tauzin and his son for professional services.
• Unpaid acquisition consideration of $100,000 as of December 31, 2024 and 2023, payable to Dr. Yu Zhou, a former director and co-chief executive officer of Beijing Genexosome.
• Redemption and Abandonment Agreement with Lab Services MSO, where the company redeemed a 40% equity interest for $1,745,000 cash and surrendered Series B Preferred Stock with a carrying value of $11,000,000. This transaction resulted in a $2,348,695 increase to additional paid-in capital.
• A $20 million Line of Credit from Chairman Wenzhao Daniel Lu, with $850,000 outstanding at December 31, 2023, which was fully repaid or reclassified by December 31, 2024. Interest expense was $42,445 in 2024 and $33,712 in 2023.
• Membership Interest Purchase Agreement with Chairman Wenzhao Daniel Lu for him to acquire 30% of Avalon RT 9 for $3,000,000, with an option for an additional 70% for $7,000,000. The company received advances of $3,108,106 in 2024 and $485,714 in 2023.
• Exchange of 9,000 shares of Series A Preferred Stock ($9,000,000 carrying value) for 5,000 shares of Series D Preferred Stock with Chairman Wenzhao Daniel Lu on January 9, 2025, resulting in a $162,473 deemed contribution to additional paid-in capital.

Stakeholder Impact

• Shareholders: Will vote on director elections and auditor ratification. Experience significant value erosion as indicated by the low TSR. The CEO transition introduces uncertainty but also potential for new strategic direction. Related party transactions, while providing capital, could raise questions about alignment of interests.
• Employees: The CEO transition impacts leadership. Salary reductions for the CEO and COO in 2024 indicate cost-cutting measures that could affect employee morale or future compensation.
• Management: Dr. Jin's resignation and Ms. Li's interim appointment signify a notable change in executive leadership. The remaining management team will need to navigate this transition.
• Creditors: The repayment/reclassification of the Line of Credit from Mr. Lu reduces direct debt to a related party, potentially improving the company's debt profile, though other related party advances exist.

Next Steps

• Elect six director nominees at the Annual Meeting on December 30, 2025.
• Ratify the appointment of M&K CPAS, PLLC as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
• The Board will continue its search for a director to fill the vacancy created by Dr. Jin's resignation.
• The acquisition of 30% of Avalon RT 9 by Mr. Lu is expected to close in the fourth quarter of 2025.
• Monthly payments from the Lab Services MSO redemption will continue until December 2026.

Key Dates

Recommendation

The company exhibits significant red flags for investors. The Total Shareholder Return (TSR) has plummeted from $100 to $4 over two years, indicating severe value destruction. While the net loss improved, the company remains unprofitable. The CEO's resignation due to health issues, followed by an interim appointment, creates leadership instability. Furthermore, the extensive and complex related-party transactions, particularly with the Chairman, raise corporate governance concerns regarding potential conflicts of interest and the fairness of terms. These factors collectively suggest a high-risk investment with a poor track record of shareholder returns and potential governance issues, warranting a 'sell' recommendation.

Keywords

Avalon GloboCare, ALBT, Proxy Statement, Annual Meeting, Director Election, CEO Resignation, Interim CEO, Corporate Governance, Financial Results, Related Party Transactions, SEC Filing, Biotechnology, Healthcare